Derenik Sarkisovich Khachatryan

Dr. Derenik Sarkisovich Khachatryan


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Molecules
Verified
Journal Article
Open access
PDF file
AFAleksandr Filimonov
Aleksandr Filimonov
ACArina Chepanova
Arina Chepanova
OLOlga Luzina
Olga Luzina
AZAlexandra Zakharenko
Alexandra Zakharenko
OZOlga Zakharova
Olga Zakharova
Olga LavrikOlga Lavrik
Olga Lavrik
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a promising therapeutic target in cancer therapy. Combination chemotherapy using Tdp1 inhibitors as a component can potentially improve therapeutic response to many chemotherapeutic regimes. A new set of usnic acid derivatives with hydrazonothiazole pharmacophore moieties were synthesized and evaluated as Tdp1 inhibitors. Most of these compounds were found to be potent inhibitors with IC50 values in the low nanomolar range. The activity of the compounds was verified by binding experiments and supported by molecular modeling. The ability of the most effective inhibitors, used at non-toxic concentrations, to sensitize tumors to the anticancer drug topotecan was also demonstrated. The order of administration of the inhibitor and topotecan on their synergistic effect was studied, suggesting that prior or simultaneous introduction of the inhibitor with topotecan is the most effective.

18 March 2020 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
VOVasiliy Osipov
Vasiliy Osipov
DKDerenik Sarkisovich Khachatryan
Derenik Sarkisovich Khachatryan
ABAlexandr N. Balaev
Alexandr N. Balaev

11 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ABAnna Bychkova
Anna Bychkova
MYMarina N. Yakunina
Marina N. Yakunina
MLMariia V. Lopukhova
Mariia V. Lopukhova
YDYevgeniy N. Degtyarev
Yevgeniy N. Degtyarev
MMMikhail Motyakin
Mikhail Motyakin
DKDerenik Sarkisovich Khachatryan
Derenik Sarkisovich Khachatryan
Magnetic nanosystems (MNSs) consisting of magnetic iron oxide nanoparticles (IONPs) coated by human serum albumin (HSA), commonly used as a component of hybrid nanosystems for theranostics, were engineered and characterized. The HSA coating was obtained by means of adsorption and free radical modification of the protein molecules on the surface of IONPs exhibiting peroxidase-like activity. The generation of hydroxyl radicals in the reaction of IONPs with hydrogen peroxide was proven by the spin trap technique. The methods of dynamic light scattering (DLS) and electron magnetic resonance (EMR) were applied to confirm the stability of the coatings formed on the surface of the IONPs. The synthesized MNSs (d ~35 nm by DLS) were intraarterially administered in tumors implanted to rats in the dose range from 20 to 60 μg per animal and studied in vivo as a contrasting agent for computed tomography. The long-term (within 14 days of the experiment) presence of the MNSs in the tumor vascular bed was detected without immediate or delayed adverse reactions and significant systemic toxic effects during the observation period. The peroxidase-like activity of MNSs was proven by the colorimetric test with o-phenylenediamine (OPD) as a substrate. The potential of the synthesized MNSs to be used for theranostics, particularly, in oncology, was discussed.

1 February 2015 in Russian Chemical Bulletin
Verified
Journal Article
Closed access
PDF file
DKDerenik Sarkisovich Khachatryan
Derenik Sarkisovich Khachatryan
ARA. L. Razinov
A. L. Razinov
AKAnton V. Kolotaev
Anton V. Kolotaev
SBS. K. Belus´
S. K. Belus´
KMK. R. Matevosyan
K. R. Matevosyan

3 July 2022 in SAR and QSAR in Environmental Research
Verified
Journal Article
Closed access
OTOleg V Tinkov
Oleg V Tinkov
VGVeniamin Grigorev
Veniamin Grigorev
LGL.D. Grigoreva
L.D. Grigoreva
VOVasiliy Osipov
Vasiliy Osipov
AKAnton V. Kolotaev
Anton V. Kolotaev
DKDerenik Sarkisovich Khachatryan
Derenik Sarkisovich Khachatryan
Histone deacetylase inhibitors represent the most important class of drugs for the treatment of human cancer and other diseases due to their influence on cell growth, differentiation, and apoptosis. Among the well-known eighteen histone deacetylases, histone deacetylase 6 (HDAC6), which is involved in oncogenesis, cell survival, and cancer cell metastasis, is of great importance. Using the CDK and alvaDesc molecular descriptors and the Random Forest and EXtreme Gradient Boosting methods, we propose a number of adequate QSAR classification models, which are integrated into a consensus model and are freely available on the OCHEM web platform (https://ochem.eu). The consensus QSAR model is used for virtual screening of a series of seven new compounds, the derivatives of N-((hydroxyamino)-oxoalkyl)-2-(quinazoline-4-ilamino)-benzamides, the synthesis schemes of which are also presented in this work. In vitro evaluation of the inhibitory activity (IC50) of this series of compounds against HDAC6 allowed us to confirm the results of virtual screening and to reveal promising compounds V-2 and V-4, IC50 of which is 3.25 nM and 0.04 nM, respectively. The subsequent in silico evaluation of the main ADMET properties of active compounds V-2 and V-4 allowed us to find that they have acceptable pharmacokinetic parameters and level of acute toxicity.

1 December 2016 in Russian Chemical Bulletin
Verified
Journal Article
Closed access
PDF file
ABA. N. Balaev
A. N. Balaev
VOV. N. Osipov
V. N. Osipov
KOK. A. Okhmanovich
K. A. Okhmanovich
ERE. A. Ruchko
E. A. Ruchko
MBM. A. Baryshnikova
M. A. Baryshnikova
DKDerenik Sarkisovich Khachatryan
Derenik Sarkisovich Khachatryan